Sariyeva Ismayılov Ayna, Esen Ebru, Sızmaz Selçuk, Demircan Ayşe Nihal
Department of Ophthalmology, Çukurova University Faculty of Medicine, Adana, Turkey.
Clin Exp Optom. 2019 Nov;102(6):617-620. doi: 10.1111/cxo.12877. Epub 2019 Feb 22.
The purpose of this study was to investigate changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (SCT) after intravitreal aflibercept injections for neovascular age-related macular degeneration (NV-AMD).
Eighty-nine eyes (48 treatment naive, 41 resistant) were included in this prospective study. All patients were treated with three consecutive monthly injections then every two months as required. BCVA, CMT and SCT were recorded and compared within and between the two groups.
The mean increase in BCVA after injections was 0.18 ± 0.34 logMAR in the naive group (p = 0.01) and 0.092 ± 0.38 logMAR in the resistant group (p = 0.131). The mean decrease in CMT was 200.3 ± 216.1 μm in the naive group and 183.3 ± 203.4 μm in the resistant group (p < 0.001 for both). The mean decrease in SCT was 22.1 ± 62.0 μm in the naive group (p = 0.014). The mean change in SCT was 22.28 ± 74.05 μm in the resistant group; this was not statistically significant (p = 0.061).
BCVA, CMT and SCT decreased significantly after intravitreal aflibercept injections in naive patients with NV-AMD. Despite anatomic success, functional improvement was not reached and SCT did not significantly decrease after intravitreal aflibercept injections in resistant patients.
本研究旨在调查玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性（NV-AMD）后最佳矫正视力（BCVA）、中心黄斑厚度（CMT）和黄斑中心凹下脉络膜厚度（SCT）的变化。
本前瞻性研究纳入了89只眼（48只初治眼，41只抵抗性眼）。所有患者均连续每月注射3次，然后根据需要每两个月注射一次。记录并比较两组内及两组间的BCVA、CMT和SCT。
初治组注射后BCVA平均提高0.18±0.34 logMAR（p = 0.01），抵抗性组为0.092±0.38 logMAR（p = 0.131）。初治组CMT平均降低200.3±216.1μm，抵抗性组为183.3±203.4μm（两组p均<0.001）。初治组SCT平均降低22.1±62.0μm（p = 0.014）。抵抗性组SCT的平均变化为22.28±74.05μm；差异无统计学意义（p = 0.061）。
初治的NV-AMD患者玻璃体内注射阿柏西普后，BCVA、CMT和SCT显著降低。尽管解剖学上取得了成功，但在抵抗性患者中，玻璃体内注射阿柏西普后未实现功能改善，SCT也未显著降低。
